SPRY2, sprouty RTK signaling antagonist 2, 10253

N. diseases: 111; N. variants: 3
Disease: Colon Carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.070 Biomarker disease BEFREE Here we have dissected SPRY2 action in human colon cancer. 26455323 2016
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.070 Biomarker disease BEFREE Increased nuclear localization of p21(WAF1/CIP1) in SPRY2 downregulated colon cancer cells may explain the inhibition of cell proliferation in colon cancer cells. 26293890 2016
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.070 Biomarker disease BEFREE Our data reveal SPRY2 as a novel Wnt/β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. 23624922 2014
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.070 AlteredExpression disease BEFREE Expression of Spry2 inhibited the growth of a colon cancer cell line, HCT116, and induced sensitization to fluorouracil (5-FU) and metformin. 22322462 2012
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.070 AlteredExpression disease BEFREE Furthermore, overexpression of Spry2 suppressed the growth and migration of colon cancer cells with a concomitant increase in PTEN expression and reduction of Akt and MAPK phosphorylation. 21099344 2011
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.070 AlteredExpression disease BEFREE In this study, we show that SPRY2 expression in colon cancer cells is inhibited by the active vitamin D metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) through E-cadherin-dependent and -independent mechanisms. 20543868 2010
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.070 Biomarker disease BEFREE The effect of Spry2 on the treatment of gefitinib, a tyrosine kinase inhibitor of EGFR, with regards to colon cancer is still unclear. 20624167 2010